These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36894328)

  • 1. In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule
    Blackwell DJ; Smith AN; Do T; Gochman A; Schmeckpeper J; Hopkins CR; Akers WS; Johnston JN; Knollmann BC
    J Pharmacol Exp Ther; 2023 Jun; 385(3):205-213. PubMed ID: 36894328
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gochman A; Do TQ; Kim K; Schwarz JA; Thorpe MP; Blackwell DJ; Ritschel PA; Smith AN; Rebbeck RT; Akers WS; Cornea RL; Laver DR; Johnston JN; Knollmann BC
    Mol Pharmacol; 2024 Feb; 105(3):194-201. PubMed ID: 38253398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic.
    Batiste SM; Blackwell DJ; Kim K; Kryshtal DO; Gomez-Hurtado N; Rebbeck RT; Cornea RL; Johnston JN; Knollmann BC
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):4810-4815. PubMed ID: 30792355
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Gochman A; Do TQ; Kim K; Schwarz JA; Thorpe MP; Blackwell DJ; Smith AN; Akers WS; Cornea RL; Laver DR; Johnston JN; Knollmann BC
    bioRxiv; 2023 Jul; ():. PubMed ID: 37461611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RyR2 Binding of an Antiarrhythmic Cyclic Depsipeptide Mapped Using Confocal Fluorescence Lifetime Detection of FRET.
    Šeflová J; Schwarz JA; Smith AN; Svensson B; Blackwell DJ; Phillips TA; Nikolaienko R; Bovo E; Rebbeck RT; Zima AV; Thomas DD; Van Petegem F; Knollmann BC; Johnston JN; Robia SL; Cornea RL
    ACS Chem Biol; 2023 Oct; 18(10):2290-2299. PubMed ID: 37769131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selective RyR2 inhibitor ent-verticilide suppresses atrial fibrillation susceptibility caused by Pitx2 deficiency.
    Kim K; Blackwell DJ; Yuen SL; Thorpe MP; Johnston JN; Cornea RL; Knollmann BC
    J Mol Cell Cardiol; 2023 Jul; 180():1-9. PubMed ID: 37080450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
    Savio-Galimberti E; Knollmann BC
    PLoS One; 2015; 10(6):e0131179. PubMed ID: 26121139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
    Kobayashi S; Yano M; Uchinoumi H; Suetomi T; Susa T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Yamamoto T; Matsuzaki M
    Circ J; 2010 Nov; 74(12):2579-84. PubMed ID: 20944434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
    Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K
    PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
    Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
    Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
    Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ryanodine receptor 2 inhibition reduces dispersion of cardiac repolarization, improves contractile function, and prevents sudden arrhythmic death in failing hearts.
    Joshi P; Estes S; DeMazumder D; Knollmann BC; Dey S
    Elife; 2023 Dec; 12():. PubMed ID: 38078905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
    Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
    EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.